Given its multifaceted impact on these processes, FXR has emerged as a significant pharmacological target in NASH treatment, evidenced by the diversity of FXR agonists currently undergoing clinical trials [272]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.